Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 17/20 | 0.93 |
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 17/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL27496757 | 1.00 | CHRM2 (0.93) | CHRM2CHRM1CHRM3 | |
| Fumaric Acid SCHEMBL6587545 | 1.00 | CHRM2 (0.93) | CHRM2CHRM1CHRM3 | |
| Fumaric Acid SCHEMBL27482727 | 0.98 | CHRM2 (0.89) | CHRM2CHRM1CHRM3 | |
| Fumaric Acid SCHEMBL6589977 | 0.98 | CHRM2 (0.89) | CHRM2CHRM1CHRM3 | |
| Fumaric Acid SCHEMBL6589985 | 0.98 | CHRM2 (0.89) | CHRM2CHRM1CHRM3 | |
| SCHEMBL508756 | 0.96 | CHRM2 (1.00) | CHRM2CHRM1CHRM3 | |
| SCHEMBL508757 | 0.96 | CHRM2 (1.00) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6589251 | 0.95 | CHRM2 (0.98) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6586888 | 0.94 | CHRM2 (0.96) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6588733 | 0.94 | CHRM2 (0.96) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285141-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2022-03-29 | — | — | US | claimed |
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4588520-A2 | COMPOSITION MODULATING BOTULINUM NEUROTOXIN EFFECT | Fastox Pharma SA (CH) | 2025-07-23 | — | — | EP | disclosed |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | Vima Therapeutics, Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240366583-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2024-11-07 | — | — | US | disclosed |
| US-12102628-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation | 2024-10-01 | — | — | US | disclosed |
| EP-3654964-B1 | COMPOSITION COMPRISING ATROPINE AND A MIOTIC AGENT AND ITS USE IN THE TREATMENT OF MYOPIA | SEINDA PHARMACEUTICAL GUANGZHOU CORP (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20240100039-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2023-03-02 | — | — | US | disclosed |
| US-20230018920-A1 | COMPOSITION MODULATING BOTULINUM NEUROTOXIN EFFECT | FASTOX PHARMA SA (CH) | 2023-01-19 | — | — | US | disclosed |
| EP-3986440-A1 | COMPOSITION MODULATING BOTULINUM NEUROTOXIN EFFECT | Fastox Pharma SA (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-114269384-A | Compositions for modulating the effects of botulinum neurotoxins | 法斯托克斯制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11285141-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2022-03-29 | — | — | US | disclosed |
| EP-0823423-B1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM3 1/4885CHRM1 8/4885 |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM3 1/4885CHRM1 8/4885 |
| US-12102628-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | CHRM2 2/4885CHRM3 1/4885CHRM1 13/4885 |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | CASR, ORAI1, TRPC3 | CHRM2 1503/4885CHRM3 894/4885CHRM1 1904/4885 |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM3 1/4885CHRM1 8/4885 |
| US-11285141-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | CHRM2 2/4885CHRM3 1/4885CHRM1 13/4885 |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM5, CHRM4, CHRM2 | CHRM2 3/4885CHRM3 4/4885CHRM1 11/4885 |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | CHRM3, CHRM2, MYOC | CHRM2 2/4885CHRM3 1/4885CHRM1 13/4885 |
| US-20240366583-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRNA5, CHRNA7 | CHRM2 7/4885CHRM3 1/4885CHRM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.